GlassScriptPhysician profile
Leo K Edwards
NPI 1750313441
$7,138.68
in general payments reported to CMS, 2019-2025
53 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,026 · 2020: $1,196 · 2021: $1,214 · 2022: $1,026 · 2023: $1,237 · 2024: $983 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,569 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,568.97 |
| Education | $108.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $648.93 | 2020-2025 | Vraylar, Ubrelvy, Linzess |
| Avanir Pharmaceuticals, INC. | $601.45 | 2019-2022 | |
| Pfizer INC. | $520.88 | 2019-2025 | |
| Amgen INC. | $512.40 | 2021-2025 | Otezla, Repatha, Krystexxa |
| Lilly USA, LLC | $420.46 | 2020-2024 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $391.04 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $381.14 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Ucb, INC. | $328.66 | 2019-2023 | Nayzilam |
| Otsuka America Pharmaceutical, INC. | $324.40 | 2023-2024 | Nuedexta |
| Abbott Laboratories | $271.16 | 2021-2024 | Freestyle Libre 3, Proclaim |
| Sunovion Pharmaceuticals INC. | $261.58 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $231.54 | 2020-2023 | Verquvo, Belsomra |
| Sumitomo Pharma America, INC. | $180.04 | 2023-2024 | Gemtesa, Aptiom |
| Amarin Pharma, INC. | $171.45 | 2019-2021 | |
| Astellas Pharma US INC | $150.33 | 2021-2023 | Myrbetriq |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.